DMD clinical studies evolve with emphasis on building designs around relevant endpoints [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
in Duchenne muscular dystrophy (DMD) indicates that choosing the right trial endpoint remains an evolving paradigm. Experts say it is notoriously difficult to evaluate the heterogeneous disease in a clinical setting, as subtle changes are heavily dependent on the stage of the disease. This, they say, is all the more reason to double down on choosing the right endpoint to evaluate any improvements. Companies have taken different approaches to tackle this. While Capricor Therapeutics succeeded in demonstrating positive three-year data with the Performance of Upper Limb (PUL 2.0) assessment in the HOPE-2 open label extension study of the cell therapy CAP-1002, big name developers such as Pfizer and Sarepta Therapeutics notably failed to demonstrate improvements using the North Star Ambulatory Assessment (NSAA). In June 2024, Pfizer shared that the pivotal Phase III study of its gene therapy, fordadistrogene movaparvovec, failed to demonstrate superiority against placebo when evalua
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesGlobeNewswire
- Things Look Grim For Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Today's Downgrade [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
CAPR
Earnings
- 8/7/24 - Miss
CAPR
Analyst Actions
- 7/2/24 - HC Wainwright
CAPR
Sec Filings
- 8/23/24 - Form SC
- 8/23/24 - Form 3
- 8/9/24 - Form 4
- CAPR's page on the SEC website